Showing results (41-50 of 65) with videos related to
Sort By:
Pageof 7
Therapeutic Advances in Endocrinology and Metabolism|September 12, 2025
Impact of Graves' hyperthyroidism treatment on lipid profiles and cholesterol dynamics: a prospective observational studyTomoko Nagamine, Kyoko Tanimura-Inagaki, Mototsugu Nagao, et al.Pathology International|June 25, 2026
Glomerular Capillary Microaneurysms in Membranoproliferative Glomerulonephritis: A Clinicopathological Study Highlighting the Involvement of IgG3Akiko Mii, Tomohiro Kaneko, Momoko Arai, et al.Journal of Diabetes Investigation|December 21, 2024
Perceptions, attitudes, and management of obesity in East Asians vs global: A pooled analysis of the ACTION IO surveyJae-Heon Kang, Soo Lim, Jee-Hyun Kang, et al.Respiratory Investigation|April 18, 2021
Diagnostic prediction of COVID-19 based on clinical and radiological findings in a relatively low COVID-19 prevalence areaYosuke Amano, Hidenori Kage, Goh Tanaka, et al.Diabetes, Obesity & Metabolism|September 3, 2024
Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational studyTaeang Arai, Masanori Atsukawa, Akihito Tsubota, et al.The Journal of Biological Chemistry|April 21, 2011
Crystal structure of the Ca²⁺/calmodulin-dependent protein kinase kinase in complex with the inhibitor STO-609Mutsuko Kukimoto-Niino, Seiko Yoshikawa, Tetsuo Takagi, et al.Acta Crystallographica. Section D, Biological Crystallography|May 6, 2011
Structural basis for compound C inhibition of the human AMP-activated protein kinase α2 subunit kinase domainNoriko Handa, Tetsuo Takagi, Shinya Saijo, et al.JGH Open : an Open Access Journal of Gastroenterology and Hepatology|April 4, 2024
Impact of pemafibrate in patients with metabolic dysfunction-associated steatotic liver disease complicated by dyslipidemia: A single-arm prospective studyHiroki Ono, Masanori Atsukawa, Akihito Tsubota, et al.Communications Biology|August 16, 2020
Human adiponectin receptor AdipoR1 assumes closed and open structuresHiroaki Tanabe, Yoshifumi Fujii, Miki Okada-Iwabu, et al.Nature|November 1, 2013
A small-molecule AdipoR agonist for type 2 diabetes and short life in obesityMiki Okada-Iwabu, Toshimasa Yamauchi, Masato Iwabu, et al.Pageof 7